### Citation

### Published Version
doi:10.1021/cb500230b

### Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:17820830

### Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Identification of a Small Molecule that Increases Hemoglobin Oxygen Affinity and Reduces SS Erythrocyte Sickling

Akito Nakagawa, Francine E. Lui, Dina Wassaf, Revital Yefidoff-Freedman, Dominick Casalena, Michelle A. Palmer, Jacqueline Meadows, Andrea Mozzarelli, Luca Ronda, Oshea Abdulmalik, Kenneth D. Bloch, Martin K. Sato, and Warren M. Zapol

ABSTRACT: Small molecules that increase the oxygen affinity of human hemoglobin may reduce sickling of red blood cells in patients with sickle cell disease. We screened 38,700 compounds using small molecule microarrays and identified 427 molecules that bind to hemoglobin. We developed a high-throughput assay for evaluating the ability of the 427 small molecules to modulate the oxygen affinity of hemoglobin. We identified a novel allosteric effector of hemoglobin, di(S-(2,3-dihydro-1,4-benzodioxin-2-yl)-4H-1,2,4-triazol-3-yl)disulfide (TD-1). TD-1 induced a greater increase in oxygen affinity of human hemoglobin in solution and in red blood cells than did 5-hydroxymethyl-2-furfural (5-HMF), N-ethylmaleimide (NEM), or diformamidine disulfide. The three-dimensional structure of hemoglobin complexed with TD-1 revealed that monomeric units of TD-1 bound covalently to β-Cys93 and β-Cys112, as well as noncovalently to the central water cavity of the hemoglobin tetramer. The binding of TD-1 to hemoglobin stabilized the relaxed state (R3-state) of hemoglobin. TD-1 increased the oxygen affinity of sickle hemoglobin and inhibited in vitro hypoxia-induced sickling of red blood cells in patients with sickle cell disease without causing hemolysis. Our study indicates that TD-1 represents a novel lead molecule for the treatment of patients with sickle cell disease.

Supporting Information

Sickle cell disease (SCD) is an inherited disorder that affects millions of people throughout the world and an estimated 70,000–100,000 people in the United States.1 Under hypoxic conditions, deoxygenated sickle hemoglobin (deoxyHbs) polymerizes and distorts sickle cell red blood cells (SS RBCs) into a rigid and sickled shape, causing occlusion and thrombosis in small blood vessels.2–4 To treat SCD, various compounds have been developed, including molecules that increase the concentration of fetal hemoglobin (Hbf).3,4 Inhibit polymerization of Hbs,5,6 promote SS RBC hydration or prevent dehydration of SS RBCs,5 and prevent adhesion of SS RBCs to capillary endothelium.7 Used clinically, hydroxyurea treats SCD by increasing the concentration of Hbf in SS RBCs, because Hbf does not enter in Hbs polymers.3,4 Increasing the oxygen affinity of Hbs represents a potential therapeutic strategy for SCD, because increased oxygen affinity leads to a decrease in the fraction of deoxyHbs.2,5,8 A variety of allosteric effectors have been identified that increase the oxygen affinity of hemoglobin including aromatic aldehydes,9–11 isothiocyanates,12 acyl salicylates derivatives,13,14 methyl acetyl phosphate,15 disulfides,16 and maleimides.17 These molecules bind to hemoglobin and preferentially stabilize the relaxed or R-state of hemoglobin relative to the tense or T-state,18–20 shifting the R to T state equilibrium toward the R-state, which has a higher oxygen affinity.11,19,21 For example, the aromatic aldehyde, 5-hydroxymethyl-2-furfural (5-HMF), increases the oxygen affinity of hemoglobin and is undergoing clinical studies as a treatment for SCD.9,11

Received: March 28, 2014
Accepted: July 25, 2014
Published: July 25, 2014
For an allosteric effector to be a safe and effective treatment for SCD, the compound should be highly specific for hemoglobin and moderately increase the oxygen affinity without causing hemolysis at efficacious doses. To date, no rational design has been reported to confer all of these properties to small molecules. We therefore sought to identify novel allosteric effectors from a compound library with diverse chemical scaffolds.\(^22\)

We report the identification of a novel allosteric effector for hemoglobin that was discovered by sequential high-throughput screening of small molecules to ascertain their abilities, first, to bind to hemoglobin using small molecule microarrays (SMMs)\(^23\) and, subsequently, to modulate the oxygen affinity of hemoglobin. Using X-ray crystallography, we revealed the three-dimensional structure of the hemoglobin-effector complex and identified the hemoglobin-binding sites of the allosteric effector, thus providing a rational explanation for its allosteric properties. Moreover, we demonstrated that the allosteric effector increases the oxygen affinity of Hbs and inhibits in vitro sickling of SS RBCs under hypoxic conditions without causing hemolysis.

**RESULTS AND DISCUSSION**

**Identification of Compounds that Bind to Hemoglobin Using Small Molecule Microarrays.** Compounds that selectively bind to hemoglobin were sought by screening 38,700 compounds that were affixed to glass slides as SMMs.\(^24\) The screened compounds included known bioactive species and chemicals from the Broad Institute of Harvard and MIT diversity-oriented synthesis library.\(^22\) The SMMs were incubated in an aqueous solution of hemoglobin and then rinsed. Compounds that bind to hemoglobin were detected using a primary antibody directed against hemoglobin followed by a dye-labeled antibody directed against the primary antibody. The assay was validated by confirming the binding of hemoglobin to 2,3-diphosphoglycerate (2,3-DPG), a naturally occurring allosteric effector,\(^25\) which was fixed on the microarray (Supporting Information Figure S1). We identified 427 small molecules that bind to hemoglobin, resulting in a hit rate of about 1% (Supporting Information Table S1).

**Identification of Allosteric Effectors of Hemoglobin Using a Novel High-Throughput Hemoglobin Oxygen Binding Assay.** To identify compounds that alter the oxygen affinity of hemoglobin from among the 427 hemoglobin binders, we developed a novel high-throughput hemoglobin oxygen binding assay (Supporting Information Figure S2). This assay is based on the spectrophotometric evaluation of the fraction of oxygenated hemoglobin (oxyHb\%) and oxidized hemoglobin (methHb\%)\(^26,27\) in 384-well plates. The assay was validated by measuring oxyHb\% and methHb\% in 2,3-DPG assay (Supporting Information Figure S2). This assay is based on the spectrophotometric evaluation of the fraction of oxygenated hemoglobin (oxyHb\%) and oxidized hemoglobin (methHb\%)\(^26,27\) in 384-well plates. The assay was validated by measuring oxyHb\% and methHb\% in 2,3-DPG assay (Supporting Information Figure S2).

The ODC of hemoglobin was measured after mixing with freshly prepared DMSO solutions of compound 1 prepared in DMSO two or more months prior to mixing with hemoglobin, the P\(_{50}\) was 18 ± 0.3 Torr (data mean value ± s.d.). When the ODC was measured using a stock solution of compound 1 prepared in DMSO two or more months prior to mixing with hemoglobin, the P\(_{50}\) was 18 ± 0.1 Torr (120 μM compound 1) and 10 ± 0.5 Torr (2 mM compound 1, P < 0.001 vs in the absence of compound 1). The decrease of P\(_{50}\) by compound 1 was in agreement with the result of the high-throughput assay showing an increase in oxyHb\%.

**Identification of the Disulfide Form of Compound 1 (TD-1) that Markedly Increases Hemoglobin Oxygen Affinity.** Compound 1 contains a triazole ring and a benzodioxine group (Figure 1B). It is the only thiol among the 427 compounds that binds to hemoglobin. It is known that thiols can be oxidized to disulfides, and disulfides have been reported to increase the oxygen affinity of hemoglobin.\(^16\) We hypothesized that the disulfide form of compound 1, triazole disulfide (TD-1, Figure 1C), rather than compound 1 itself, increased oxyHb\% in the high-throughput assay and decreased P\(_{50}\) in the ODC measurement. To test this hypothesis, the ODC of hemoglobin was measured after mixing with freshly prepared DMSO solutions of compound 1 or TD-1. When hemoglobin (20 μM tetramer) was mixed with compound 1 (120 μM) at 37 °C, and the ODC was measured after 10 min of incubation, the P\(_{50}\) was 17 ± 0.1 Torr. In contrast, incubation of hemoglobin with TD-1 markedly shifted the ODC to the

![Figure 1](https://doi.org/10.1021/cb500230b)
The P50 of whole blood mixed with TD-1 (20, 40, 80, and 120 μM) in Hemox solution with 0.8 vol% DMSO at 37 °C was measured. Error bars represent the mean value of P50 measured in triplicate. Figure 2. TD-1 increases the oxygen affinity of normal human hemoglobin (Hb) and whole blood. (A) The ODC of hemoglobin (Hb, 20 μM as tetramer) without and with TD-1 (120 μM in DPBS, pH 7.4, with 5 vol% DMSO) at 37 °C. (B) The P50 of hemoglobin mixed without and with Compound 1 (120 μM) or TD-1 (20, 40, 80, and 120 μM). (C) Relationship between pH and P50 of hemoglobin (20 μM) with and without addition of TD-1 (120 μM) in 0.1 M phosphate buffer (pH 6-8) with 5 vol% DMSO at 37 °C. (D) The ODC of whole blood without or with TD-1 (40 μM, 2:1 molar ratio to Hb tetramer) in Hemox solution with 0.8 vol% DMSO at 37 °C. (E) The P50 of whole blood mixed with TD-1 (20, 40, 80, and 120 μM). Each symbol represents the mean value of P50 measured in triplicate. (F) The P50 of whole blood mixed with TD-1 (40 μM), 5-HMF, formamidine disulfide, and NEM (all 120 μM). Each bar represents the mean value of P50 measured in triplicate. Error bars represent standard deviation.

TD-1 on the ODC was dose-dependent with efficacy observed even when the molar ratio of compound to hemoglobin was 1:1 (P50 12 ± 0.3 Torr; P < 0.001 vs without TD-1; Figure 2B). Incubation of hemoglobin with TD-1 reduced the Bohr effect (the increase of the P50 of hemoglobin induced by decreasing the pH).29 (∆log P50)/∆pH was −0.08 ± 0.02 vs −0.37 ± 0.04, with and without TD-1 (at a 6:1 molar ratio of TD-1 to hemoglobin), respectively (P < 0.001, Figure 2C).

To test whether TD-1 could reduce the P50 of hemoglobin in RBCs, we incubated whole blood (hemoglobin 0.13 g dL⁻¹) from healthy human donors with TD-1 (40 μM; 2:1 molar ratio of TD-1 to hemoglobin) for 10 min at 37 °C, and the ODC was measured. TD-1 decreased the P50 from 27 ± 0.5 to 8.5 ± 0.3 Torr (P < 0.001, Figure 2D). The impact of TD-1 on the ODC was dose-dependent with efficacy observed even when the ratio of compound to hemoglobin was 1:1 (P50 22 ± 1.4 Torr; P < 0.001 vs without TD-1; Figure 2E). TD-1 (40 μM) reduced the P50 of whole blood greater than did other small molecules previously reported to increase the oxygen affinity of hemoglobin (Figure 2F). For example, at a 6:1 molar ratio of compound to hemoglobin, 5-HMF did not change the P50 (P50 = 26 ± 0.5 Torr), and NEM (P50 = 20 ± 1.1 Torr; P < 0.001 vs 40 μM TD-1) and formamidine disulfide (P50 = 23 ± 0.6 Torr; P < 0.001 vs 40 μM TD-1) had only modest effects. Taken together, these results indicate that TD-1 potently augments the oxygen affinity of hemoglobin in blood.

Three-Dimensional Structure of the Hemoglobin Complexed with TD-1 Revealed by X-ray Crystallography. To investigate how TD-1 increases the oxygen affinity of hemoglobin, carboxyhemoglobin (COHb) was cocrystallized with a 10-fold molar excess of TD-1. We used COHb in the crystallographic studies since COHb is much more stable than oxyHb, which has the propensity to oxidize to metHb under ambient conditions. We obtained needle crystals of hemoglobin in the R3 state, one of the R state conformers.11,18,30 Detailed crystallographic and structural analysis parameters are reported in Supporting Information Table S4. The tetrameric structure of the R3 state revealed that eight monomeric units (MUs) of TD-1 were bound to hemoglobin (Figure 3A). Two MUs were located on the surface of hemoglobin forming a disulfide bond with β-Cys93 (MU-1/MU-1; Figure 3B and Supporting Information Figure S3). The covalent binding of a MU to β-Cys93 resulted in significant tertiary and quaternary structural changes in hemoglobin as compared to the R3 structure in the absence of TD-1 (PDB code: 1YZJ; Figure 3B and C). These changes include movement of the EF corner, F helix, and heme toward the interdimer interface and a narrower β-cleft and central water cavity that should lead to further stabilization of the R-state, as previously reported30 (Figure 3B). Similar structural movements are also observed when purified deoxyHb binds oxygen or CO (transition from T to the classical R state or from T to R3 state).18 Two other MUs formed disulfide bonds with the two β-Cys112 residues (MU-2/MU-2') located in the central water cavity. The remaining MU molecules (MU-3/MU-3' and MU-4/MU-4') were located in the water cavity interacting noncovalently with amino acid residues lining the water cavity and extensively with each other, as well as with MU-2/MU-2' further stabilizing the R-state (Figure 3D and Supporting Information Figure S7).

The high reactivity of TD-1 for covalent binding to hemoglobin is likely due to its triazole ring, which stabilizes the MU dissociated from TD-1.31,32 We observed covalent modification of hemoglobin by MU at β-Cys93 and β-Cys112 but not at α-Cys104. There are six cysteine amino acids in hemoglobin (α-Cys104, β-Cys93, and β-Cys112, and their symmetry-related pairs). β-Cys93 is exposed at the surface of hemoglobin in the oxygenated state, and β-Cys112 is located in the central water cavity, while α-Cys104 is buried in the protein’s interior. β-Cys93 is known to react with reagents such as disulfides,16,32 maleimide,32 nitric oxide,34 p-hydroxymercuribenzoate (PMB),35,36 and methyl bromide.37 α-Cys104 and β-Cys112 have been considered relatively non-reactive, since these residues are believed to be inaccessible.35 However, both PMB36 and methyl bromide37 can react with all the cysteine residues of hemoglobin. These results indicate that compounds that access the central cavity can react with the thiol of β-Cys112 even though β-Cys112 is not exposed on the surface of hemoglobin.

Stabilization of R-State (R3-state) Hemoglobin by TD-1. The crystal structure of hemoglobin bound to TD-1 suggests...
two mechanisms by which TD-1 can increase the oxygen affinity of hemoglobin. First, covalent binding of MU to β-Cys93 displaces the position of β-His146, sterically preventing the salt-bridge interaction between β-His146 and β-Asp94 in the T-state. Prevention of this salt-bridge interaction both destabilizes the T-state and stabilizes the R-state with a concomitant increase in oxygen affinity and impairment of the Bohr effect.38,39 A second mechanism by which TD-1 alters the oxygen affinity of hemoglobin is attributable to the binding of the six MUs in the central water cavity. Each of the six MUs makes hydrogen bond and/or hydrophobic interactions with the hemoglobin subunits and at least one other MU. These interactions help to tie all four hemoglobin subunits together, stabilizing the R state and restricting the subunit rotation that is required to transition to the T state.

TD-1 increased the oxygen affinity of hemoglobin in a manner different from other allosteric effectors, S-HMF, and the bifunctional acylating agent bis(3,5-dibromosalicyl)fumarate. Two S-HMF molecules form a Schiff-base interaction with the two N-terminal α-Val1 nitrogen atoms at the α-cleft of hemoglobin in the R2-state, stabilizing the relaxed state to increase hemoglobin oxygen affinity.10,40 Bis(3,5-dibromosalicyl)fumarate spans the 2,3-DPG binding site of hemoglobin41 by cross-linking with the two N-terminal α-Val1 nitrogen atoms at the α-cleft of hemoglobin in the R2-state, stabilizing the relaxed state to increase hemoglobin oxygen affinity.10,40 Bis(3,5-dibromosalicyl)fumarate spans the 2,3-DPG binding site of hemoglobin41 by cross-linking

Inhibition of Hypoxic Sickling of Red Blood Cells by TD-1. The pathophysiology of SCD is primarily driven by the polymerization of deoxyHbS. Since TD-1 increased the oxygen affinity of human adult hemoglobin (HbA), we investigated the ability of TD-1 to increase the oxygen affinity of HbS. When TD-1 was mixed with hemolysates of SS RBCs and the ODC was measured, the oxygen affinity increased in a dose-dependent manner (Figure 4A). We also investigated the ability of TD-1 to inhibit sickling of SS RBCs under experimental hypoxic conditions. SS RBCs were incubated in the presence and absence of three different concentrations (0.5, 1.5, and 2 mM) of TD-1 under hypoxic conditions (a gas mixture of 4% oxygen and 96% of nitrogen at 37 °C) for 3 h. In the absence of TD-1, deoxygenation of SS RBCs induced RBC transition from discocytes (Figure 4B) to sickled shapes (Figure 4C). Incubation of SS RBCs (hematocrit = 20%) with TD-1 prior to exposure to hypoxia reduced the percentage of sickled cells without causing hemolysis in a dose-dependent manner (Figure 4D–G). The percentage of SS RBCs was markedly reduced from 95 ± 0.3% (without addition of TD-1, mean value ± s.d.) to 11 ± 4% in the presence of TD-1 (2 mM, P < 0.001 differs vs SS RBCs incubated without TD-1). Taken together, these results demonstrate that TD-1 inhibits the sickling of human SS RBCs, likely by increasing the oxygen affinity of HbS.

The concentration of TD-1 (2 mM) required to reduce sickling of hypoxic SS RBCs by nearly 90% was less than that reported for S-HMF (5 mM).9 Moreover, it is conceivable that because of its covalent interactions with hemoglobin, TD-1 may have a more sustained effect on oxygen affinity than do other allosteric effectors that do not form covalent bonds with hemoglobin. As a relevant corollary, our findings indicate that the binding of TD-1 to hemoglobin in RBCs is not significantly blocked by plasma molecules including albumin when more than a 1:1 molar ratio of TD-1 to hemoglobin is added to blood. If the beneficial effects of TD-1 on SS RBCs in vitro can be extended to animal models and, eventually, demonstration in clinical trials, our observations suggest that TD-1 may be an important new treatment for SCD.

Figure 3. The relaxed state (R3-state) of hemoglobin is stabilized by TD-1 via covalent and non-covalent bonding. (A) Structure of R3-state hemoglobin with TD-1 as monomeric units (MUs, red sticks). α-chains of hemoglobin are blue, and β-chains are yellow. Heme is not shown for clarity. (B) Binding of MU-1/MU-1′ (red sticks) to β-Cys93 (orange sticks) induces large tertiary and quaternary structural perturbations. Hemoglobin in the absence of MUs (R3 state, PDB code 1YZI) is shown in white/grey and hemoglobin in the presence of MUs (PDB code 4N10) is shown in green. (C) Superposition of COHb without MUs (white ribbons) and COHb-MU complex (green ribbons). MU-1 is shown as red sticks. A magenta arrow represents the movement of β-His146 associated with MU-1/MU-1′ binding of Cys93. (D) Interactions of MU-2/MU-2′, MU-3/MU-3′, and MU-4/MU-4′ in the water cavity help to tie the four hemoglobin subunits together.
Conclusions. We identified 427 compounds that bind to human hemoglobin using small molecule microarrays. We developed a high-throughput assay to evaluate the ability of hemoglobin-binding molecules to alter hemoglobin’s oxygen affinity. We identified TD-1, a molecule that potently increases the oxygen affinity of both purified human hemoglobin and hemoglobin within RBCs. X-ray crystallography revealed that binding of TD-1 to hemoglobin induced stabilization of the R-state. Remarkably, TD-1 potently inhibited hypoxia-induced sickling of SS RBCs without causing hemolysis. Taken together, our findings suggest that TD-1 represents a novel lead molecule for the treatment of patients with sickle cell disease.

METHODS

Materials. A compound library containing 38,700 compounds was obtained from the Broad Institute of MIT and Harvard compound library and used for the SMM screening and in the hemoglobin oxygen assay. 2,3-DPG, IHP, NEM, and 5-HMF were purchased from Sigma-Aldrich. 5-(2,3-dihydro-1,4-benzodioxin-2-yl)-4H-1,2,4-triazole-3-thiol (compound 1) was purchased from Chengbi Corporation. Di(5-(2,3-dihydro-1,4-benzodioxin-2-yl)-4H-1,2,4-triazol-3-yl)disulfide (TD-1) was synthesized by Shanghai ChemPartner. Formamidine disulfide was purchased from Alfa Aesar.

The uses of the RBCs and whole blood for the reported studies were reviewed and approved by the Institutional Review Board (IRB) of Partners Human Research Committee. The use of blood from SCD patients for antisickling assays was reviewed and approved by the IRB at the Children’s Hospital of Philadelphia. Preparation of hemoglobin (HbA) is described in Supporting Information.

Identification of Compounds That Bind to Hemoglobin Using SMMs. Detailed methods about the preparation of SMMs and identification of compounds that bind to hemoglobin are described in Supporting Information.

Identification of Small Molecules That Alter the Oxygen Affinity of Hemoglobin. The ability of small molecules to alter the oxygen affinity of hemoglobin was determined by measuring the fraction of oxygenated hemoglobin (oxyHb%) and oxidized hemoglobin (metHb%) using spectrophotometry under three (high, medium, and low oxyHb saturation) conditions. Hemoglobin was mixed with test compounds, and the mixture was added to 240 central wells of 384-well plates (50 μL/well). The concentrations of hemoglobin, compound, and dimethyl sulfoxide (DMSO) were 10 μM, 60 μM, and 5 vol % in Dulbecco’s phosphate buffered saline (DPBS), respectively. A detailed scheme of the sample preparation is reported in Supporting Information and presented in Figure S2A.

The assay plates, a plate reader (MultiSkan GO, Thermo Fisher Scientific), a plate shaker, a thermometer, a humidity monitor, and a calibrated oxygen pressure meter were placed in an inflatable polyethylene chamber (AtmosBag, Sigma) (Supporting Information Figure S2B). The chamber was purged with a precise mixture of nitrogen and air, which was then continuously provided to control the fraction of oxygen gas in the chamber (FO2). Gas cylinders of nitrogen gas and air were connected to a gas mixer to adjust the flow rate of nitrogen gas and air to the chamber. Humidity was maintained (70–85%) in the chamber via a humidifier connected to the gas inlet. The temperature in the chamber was 25–27 °C.

For the “high oxyHb saturation” condition, the assay plates were incubated without shaking at FO2 0.012 for 12 h. The visible absorption spectra of the samples were measured from 500 to 700 nm at 2 nm steps using the plate reader. After the measurement of the absorption spectra, the plates were shaken for 1 h at FO2 0.012, and the spectra were remeasured to obtain the “medium oxyHb saturation” condition. The FO2 was then reduced to 0.005, and the plates were shaken for 1 h, and the spectra were again measured to obtain the “low oxyHb saturation” condition. To determine oxyHb% of each sample, the measured absorption spectra were analyzed by least-squared fitting to determine oxyHb% and metHb% using Solver (Excel 2007, Microsoft).

During development of the hemoglobin-oxygen binding assay, we controlled the uneven distribution of oxygenation values in 240 central wells by an adjustment factor determined for each well. This adjustment factor was determined by measuring absorption spectra of hemoglobin samples without test compounds in the 240 central wells of four plates at high, medium, and low oxyHb saturation conditions. For example, if the mean value of oxyHb% of all the 960 wells is 50%, and the mean value of oxyHb% in a well at position 3C is 47%, the adjustment factor for the well at position 3C is 50% – 47% = 3%. We found that this adjustment factor eliminated some false positives from the selection of allosteric effectors. To evaluate the ability of compounds to alter hemoglobin oxygen affinity, the value of oxyHb% was defined as the sum of oxyHb% calculated by combining the spectral deconvolution and the adjustment factor.
We selected the compounds that alter oxyHb% without increasing metHb% based on the value of the Z score for oxyHb% and metHb%. The Z score for oxyHb% \((Z_{\text{oxy}})\) was calculated for each compound according to eq 1.

\[
Z_{\text{oxy}} = \frac{\text{mean value of oxyHb\%}_\text{cpd} - \text{mean value of oxyHb\%}_\text{ctrl}}{\text{standard deviation of oxyHb\%}_\text{ctrl}}
\]  

(1)

In this equation, oxyHb\%\_cpd is the oxyHb% of hemoglobin incubated with a unique compound, and oxyHb\%\_ctrl is the oxyHb% of hemoglobin without any added compounds. The Z score for metHb\% \((Z_{\text{met}})\) was also calculated according to eq 2.

\[
Z_{\text{met}} = \frac{\text{mean value of metHb\%}_\text{cpd} - \text{mean value of metHb\%}_\text{ctrl}}{\text{standard deviation of metHb\%}_\text{ctrl}}
\]  

(2)

In this equation, metHb\%\_cpd is the metHb% of hemoglobin incubated with a unique compound, and metHb\%\_ctrl is the metHb% of hemoglobin without any added compound. We designated compounds as able to alter oxyHb% without increasing metHb% formation ("hit" compounds), if they satisfied Condition 1 (both \(Z_{\text{oxy}} > 2.5\) reflecting an increase of oxyHb%) and Condition 2 (both \(Z_{\text{met}} < -2.5\) reflecting a decrease of oxyHb%) in at least one of the three oxygen saturation conditions.

**Measurement of the Oxygen Dissociation Curve (ODC).** The ODCs of hemoglobin and whole blood were measured with a HEMOX analyzer (TCS Scientific Corporation). Detailed methods are described in Supporting Information. \(P_{50}\) was determined from three independent ODC measurements.

Statistical analysis was performed using GraphPad Prism 5 software. To compare \(P_{50}\) values at different concentrations of compound 1 and TD-1, a one-way analysis of covariance (ANOVA) with Bonferroni’s post tests was applied. The one way ANOVA with Bonferroni’s post tests was also applied to compare \(P_{50}\) values of whole blood incubated in the absence or presence of TD-1, 5-HMF, NEM, and formamidine disulfide. The slope of \((\Delta \log P_{50})/\Delta pH\) was evaluated by analysis of covariance (ANCOVA). \(P < 0.05\) was considered statistically significant.

**Crystallography of Hemoglobin with TD-1 and Data Collection.** To obtain the hemoglobin structure in complex with TD-1, a freshly prepared solution of TD-1 in DMSO was incubated with oxyHb for 1 h at 37 °C at a hemoglobin tetramer-compound molar ratio of 1:10. The mixture was saturated with carbon monoxide (CO) to generate carboxyhemoglobin (COHb). Crystallization was carried out with a solution of 20–30 mg mL\(^{-1}\) COHb, in a mixture of 3.0–3.4 M sodium monobasic phosphate and potassium phosphate dibasic, at pH values ranging from 6.4 to 7.6 using vacutainer tubes.\(^{30,42}\) One or two drops of toluene were added to the solution in each tube to facilitate crystallization. CO was bubbled into the tubes, and then sealed. X-ray-quality crystals grew in 2–3 days, with almost all the crystals as long rectangular needles, which are typical of quaternary R3-state crystals.\(^{30}\) In addition to the needle crystals, a few of the crystallization setups contained trigonal bipyrimal (octahedral) crystals: the classical quaternary R3-state crystals.\(^{30}\) Prior to study by X-ray diffraction, the crystals were washed in a cryoprotectant solution containing 50 μL mother liquor and 10–15 μL glycerol.

Diffraction data of all crystals were collected at 100 K with a Rigaku IV++ image plate detector using a Cu Kz X-rays (\(\lambda = 1.54 \text{ Å}\)) from a MicroMax-007 source fitted with Varimax Confocal optics (Rigaku). The data sets were processed with the d\textsuperscript{4}trek software (Rigaku) and the CCP4 suite of programs.\(^{43}\)

**Determination of the Structure of COHb in Complex with TD-1.** COHb in complex with TD-1 crystallized in the space group P4\(_h\)2\(_2\) with approximate unit-cell constants of \(a = 62 \text{ Å}, b = 62 \text{ Å}, c = 176 \text{ Å}\) with one dimer (αβββ) per asymmetric unit, and expectedly isomorphous to the previously published high-salt R3 state COHb crystal.\(^{30}\)

The isomorphous R3 state αβββ dimeric COHb structure (PDB code 1YZI) was used as a starting coordinate to refine the structure of COHb in complex with TD-1 using software packages CNS and Phenix.\(^{44,45}\) Model building and correction were carried out using COOT.\(^{46}\) Initial difference map of the R3 structure identified four monomeric units (MUs) of the divalent TD-1 (Supporting Information Figure S3A and S3D) and three toluene molecules (used in the crystallization experiment), which were modeled in the structure and refined (Supporting Information Figure S3B and S3E). The final crystallographic R-factor and R-free were 22.8 and 25.9, respectively. The X-ray data is summarized in Supporting Information Table S4. Structural figures in Figure 3 and Supporting Information Figures S3 and S7 were prepared with PyMol\(^{47}\) and ChemBioDraw Ultra (PerkinElmer).

**Evaluation of Antisickling Effects of TD-1.** The antisickling effect of TD-1 was evaluated according to the previously described procedure.\(^{3,48}\) Detailed methods are described in Supporting Information.

The percentage of sickled cells was obtained from four independent experiments for each condition. The percentage of sickle cells with and without TD-1 (2 mM) was compared using two-tailed, unpaired Student’s t tests (GraphPad Prism 5 software). \(P < 0.05\) was considered statistically significant.

**ASSOCIATED CONTENT**

* S Supporting Information

Detailed methods. This material is available free of charge via the Internet at http://pubs.acs.org.

**Accession Codes**

The atomic coordinates and structure factor files have been submitted to the Protein Data Bank under an accession code 4N10 for COHb with TD-1 (as R3-state with monomeric units of TD-1).

**AUTHOR INFORMATION**

**Corresponding Author**

Email: wzapol@mgh.harvard.edu.

**Notes**

The authors declare the following competing financial interest(s): Massachusetts General Hospital has filed a patent related to TD-1.

**ACKNOWLEDGMENTS**

The authors wish to acknowledge J. Winkler, PhD (University of Pennsylvania) for helpful discussions and advice, T. Asakura, MD PhD (The Children’s Hospital of Philadelphia) for providing resources to evaluate in vitro sickling of SS RBCs under hypoxic conditions, S. Johnston, PhD, and J. Athanasopoulos, PhD (The Broad Institute), for evaluating the binding of TD-1 to blood. This work was supported by grants from the National Institutes of Health/NIH Heart, Lung, and Blood Institute (NIH/NHLBI) (HL103186, O.A.) and from the Foundation LeDucq (K.D.B.). Structural biology resources were provided, in part, by NIH award CA16059 to the VCU Massey Cancer Center (M.K.S.).

**REFERENCES**


